Xenon Pharmaceuticals Inc. (XENE)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Collaboration revenue (note 9) | - | 7,500 | ||
| Research and development | 74,985 | 61,200 | ||
| General and administrative | 19,244 | 19,038 | ||
| Total operating expenses | 94,229 | 80,238 | ||
| Loss from operations | -94,229 | -72,738 | ||
| Interest income | 7,199 | 8,083 | ||
| Foreign exchange gain | 1,698 | 35 | ||
| Total other income | 8,897 | 8,118 | ||
| Loss before income taxes | -85,332 | -64,620 | ||
| Income tax recovery (expense) | -626 | 427 | ||
| Net loss | -84,706 | -65,047 | ||
| Unrealized gain (loss) on available-for-sale securities (note 5) | 949 | 776 | ||
| Comprehensive loss | -83,757 | -64,271 | ||
| Earnings per share, basic, total | -1.07 | -0.83 | ||
| Earnings per share, diluted, total | -1.07 | -0.83 | ||
| Weighted average number of shares outstanding, basic, total | 78,953,445 | 78,687,503 | ||
| Weighted average number of shares outstanding, diluted, total | 78,953,445 | 78,687,503 | ||